Drug Profile
GDC 0214
Alternative Names: GDC-0214; RG 6151Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Genentech
- Class Antiasthmatics; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 28 Apr 2021 Discontinued - Phase-I for Asthma in New Zealand (Inhalation) (Roche pipeline, March 2021)
- 08 Feb 2021 GDC 0214 is still in phase I trials for Asthma in New Zealand (Roche pipeline, February 2021)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Asthma in New Zealand (Inhalation)